BreastCancerTrials.org

BreastCancerTrials.org BreastCancerTrials.org is a free and unbiased clinical trials matching service.

Tomorrow is the day!! Join us for a free, live webinar focused on how to use BreastCancerTrials.org tools to create and ...
03/26/2026

Tomorrow is the day!!
Join us for a free, live webinar focused on how to use BreastCancerTrials.org tools to create and complete a Breast Cancer profile, a key step in finding personalized clinical trial options for treatment and care.
.org
https://quantumleaphealth-org.zoom.us/j/89451766418

Experts Weigh in on MBC Subtypes: Triple Negative MBC, Including HER2-Low and HER2-Ultralow. This month, we highlight th...
03/23/2026

Experts Weigh in on MBC Subtypes: Triple Negative MBC, Including HER2-Low and HER2-Ultralow. This month, we highlight the latest expert opinions on treatments for triple negative and HER2-low and -ultralow MBC and unanswered questions that need to be answered in clinical trials. Click to learn more about clinical trials for this subtype of MBC.
https://metastatictrialtalk.org/from-the-experts/mbc-her2-2-2/
.org

Join us for a free, live webinar focused on how to use BreastCancerTrials.org tools to create and complete a Breast Canc...
03/21/2026

Join us for a free, live webinar focused on how to use BreastCancerTrials.org tools to create and complete a Breast Cancer profile, a key step in finding personalized clinical trial options for treatment and care.

Please complete this form to RSVP to our session on Friday, March 27th at 1-2pm eastern time (ET). You will receive a Zoom invitation after completing this form.

Please email us at [email protected] or call us at (888) 282-7099 with any feedback or questions.

Our Q&A sessions are not designed to answer specific questions about your personal situation. For personalized support, click here to schedule a free appointment with our Clinical Trial Navigator: https://calendly.com/s-mayhew-quantumleaphealth/clinicaltrialnavigation
.org
https://quantumleaphealth-org.zoom.us/webinar/register/WN_-GIJL_JkRZGOCs74ZoCAXg

The FDA expanded approval for fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab (Perjeta®) as fi...
03/09/2026

The FDA expanded approval for fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab (Perjeta®) as first-line treatment of people with HER2+ MBC. Click to learn more about this new approval.
.org

We’re excited to support a new DCIS (Stage 0) education resource from Look Learn Locate — built to help patients better ...
02/13/2026

We’re excited to support a new DCIS (Stage 0) education resource from Look Learn Locate — built to help patients better understand DCIS diagnosis & treatment options. 💓

Explore it here:
https://learnlooklocate.com/stage-0-ductal-carcinoma-in-situ/

Learn what Stage 0 ductal carcinoma in situ (DCIS) means, how it’s detected with mammograms, and why early screening is key to successful outcomes.

Address

499 Illinois Avenue, Suite 200
San Francisco, CA
94158

Alerts

Be the first to know and let us send you an email when BreastCancerTrials.org posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share